Last updated on April 2018

Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic | leukemia | Myelogenous | BCR-ABL Positive
  • Age: Between 18 - 70 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Chronic Myeloid Leukaemia -CML- in chronic phase (CP)
  2. Failure to achieve at least a Major Cytogenetic Response (MCyR) after a minimum of 18 months of TKIs treatment
  3. Inability to tolerate 3 months of uninterrupted full dose TKIs therapy due to hematological toxicity
  4. A minimum of three treatment interruptions due to hematological toxicity Availability of a HLA-identical related donor (Matched Related Donor, MRD)
  5. Availability of unrelated donor (Matched Unrelated Donor, MUD) satisfying the criteria of a 10/10 antigen match at (Human Leukocyte Antigen) HLA-A, -B, -C and - DRB1, -DQB1 at high resolution typing, or 9/10 with a permissive - DP disparity according to Fleischhauer model (Crocchiolo et al, Blood 2009)
  6. Target graft size (bone marrow):
  7. bone marrow: > 3 x 106 CD34+ cells/kg BW recipient or > 3 x 108 nucleated cells/kg BW
  8. Karnofsky Index > 80 %
  9. Age 18 and 70 years
  10. Adequate contraception in female patients of child-bearing potential
  11. Written informed consent

Exclusion Criteria:

  1. Secondary malignancies
  2. A hematopoietic cell transplantation-specific comorbidity index (Sorror et al Appendix
  3. > 4
  4. Known and manifested malignant involvement of the Central Nervous System (CNS)
  5. Active infectious disease
  6. Active human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis B virus (HCV) infection
  7. Impaired liver function (Bilirubin > upper normal limit; Transaminases > 3.0 x upper normal limit)
  8. Impaired renal function (Creatinine-clearance < 60 ml/min; Serum Creatinine > 1.5 x upper normal limit).
  9. Pleural effusion or ascites > 1.0 L
  10. Pregnancy or lactation
  11. Known hypersensitivity to Busilvex and/or fludarabine 11 Non-co-operative behaviour or non-compliance 12 Psychiatric diseases or conditions that might impair the ability to give informed consent

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.